BioNTech Shares Under Pressure as FDA Memo Sparks Sector-Wide Selloff

December has opened with a jolt for BioNTech and its investors. A strategic pivot toward oncology and a critical acquisition are now overshadowed by regulatory tremors emanating from the United States. An internal memo from the U.S. Food and Drug Administration (FDA) has sent shockwaves through the biotechnology sector, raising urgent questions about the company’s near-term trajectory amid mounting challenges.

Regulatory Concerns Trigger Market Retreat

The immediate catalyst for a sharp sector decline was a document from Vinay Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER). The memo discusses a potential link between COVID-19 vaccines and fatal myocarditis, or heart inflammation, in children. It cites at least ten such cases recorded between 2021 and 2024.

Market reaction was swift and severe. BioNTech shares were caught in a broad selloff that also heavily impacted peers Moderna and Novavax. Investors are bracing for the FDA’s proposed regulatory response, which points to stricter review and approval processes. These would extend beyond measuring immune response to place greater emphasis on clinical outcomes.

Analysts at Leerink Partners described the tone of the document as “inflammatory,” warning it could reignite vaccine skepticism. For BioNTech, which is actively working to strategically refocus on oncology, this development represents a significant headwind for its core vaccine business.

CureVac Acquisition Nears Its Deadline

Compounding the regulatory pressure, BioNTech is in the final stages of a crucial takeover. The company is nearing the deadline to complete its acquisition of rival CureVac. While the official exchange offer remains open until December 3, CureVac shareholders must tender their shares by 6:00 p.m. U.S. Eastern Time today to meet certain procedural timelines.

Should investors sell immediately? Or is it worth buying BioNTech?

Structured as an all-stock transaction valued at approximately $1.25 billion, the deal aims to unite two leading pioneers in mRNA technology. With CureVac shareholders having already approved the move by an overwhelming majority, completion is considered a formality. However, the current market turmoil presents a highly unfavorable backdrop for finalizing this major strategic transaction.

Stock Performance Reflects Mounting Headwinds

The confluence of negative news and a difficult market environment is clearly visible in the share price chart. Closing at 84.05 euros on Monday, the stock continues its downward trend and is now down more than 25% since the start of the year. Despite a raised revenue forecast in November and a strong cash position bolstered by the Bristol Myers Squibb collaboration, risk perceptions currently dominate.

The stock now trades notably below all its key moving averages.

The outlook appears challenging. BioNTech is engaged on multiple fronts simultaneously. With Pfizer recently reducing its stake and the FDA signaling a tighter regulatory stance, the planned transformation into a cancer therapy specialist is becoming an obstacle course. Investors are now watching closely to see whether the integration of CureVac can reignite growth prospects or if regulatory concerns will continue to weigh on the share price.